In an interview with PharmaShots, Max Lataillade, Vice President, Head of Global Research Strategy, ViiV Healthcare shared his views on the development of Rukobia and the story of its development. He also shed light on what this approval means to the patients.
Shots:
MA for Rukobia marks a critical breakthrough for this select group of adults who…
